Arvinas vs Nurix Therapeutics
ARVN and NRIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARVN and NRIX compare
Nurix Therapeutics is the larger company, worth 3.8 times as much as Arvinas ($1.7B against $446M).
On earnings, Nurix Therapeutics is cheaper: it trades at 6.7× trailing earnings, against 42.6× for Arvinas.
Nurix Therapeutics grew revenue faster over the last twelve months (739% versus −15.0% for Arvinas).
Nurix Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.0% compared with 2.9% at Arvinas.
Nurix Therapeutics scores higher on the StockData Score (15 against 8 for Arvinas), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARVN | NRIX |
|---|---|---|
| Size and price | ||
| Market cap | $446M | $1.7B |
| Share price | $6.82 | $15.48 |
| Change, 1 year | −34.5% | 27.2% |
| Change, 5 years | −91.8% | −50.6% |
| Beta (5Y) | 1.39 | 1.46 |
| Employees | 246 | 317 |
| StockData Score | ||
| Total score | 8 | 15 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 3 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 42.6× | 6.7× (better) |
| P/S | 1.4× (better) | 2.4× |
| P/B | 0.8× (better) | 1.7× |
| EV/EBITDA | – | 2.0× |
| P/FCF | – | 4.6× |
| FCF yield | −46.8% | 21.9% (better) |
| Fair value | – | $57.66 |
| Margin of safety | – | 73.2% |
| Growth | ||
| Revenue growth (TTM) | −15.0% | 739% (better) |
| Revenue growth, 5Y average | 58.9% (better) | 36.3% |
| Profitability | ||
| Operating margin | −5.7% | 41.3% (better) |
| Net margin | 2.9% | 42.0% (better) |
| FCF margin | −65.9% | 52.7% (better) |
| Return on equity | 1.6% | 44.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 7.91 | 8.44 (better) |
| Altman Z-score | 0.65 | 6.10 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −1.1% |
| Shareholder yield | 0.00% (better) | −1.1% |
| Ownership | ||
| Held by institutions | 86.0% | 107% |
| Held by insiders | 7.8% | 3.2% |
| Insider net buying, 12 months | −$1.2M (better) | −$5.2M |
| Short interest, % of float | 9.5% | 17.9% |
Go deeper
- ARVN stock overview
- ARVN income statement
- ARVN valuation and score
- NRIX stock overview
- NRIX income statement
- NRIX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.